423TiPThe first-in-human, dose-finding PROCLAIM-CX-072...

Annals of Oncology 2017 / 09 Vol. 28; Iss. suppl_5

423TiPThe first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas

Boni, V., Garcia-Corbacho, J., Feliu, J., Wydmanski, J., Horvath, Z., Bondarenko, I., Irving, B., Will, M., de Vries, E.G.E., Thistlethwaite, F.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx367.056
Date:
September, 2017
File:
PDF, 65 KB
english, 2017
Conversion to is in progress
Conversion to is failed